Abstract:Importance: Community-acquired pneumonia (CAP) results in approximately 1.4 million emergency department visits, 740 000 hospitalizations, and 41 000 deaths in the US annually. Observations: Community-acquired pneumonia can be diagnosed in a patient with 2 or more signs (eg, temperature >38 °C or ≤36 °C; leukocyte count <4000/μL or >10 000/μL) or symptoms (eg, new or increased cough or dyspnea) of pneumonia in conjunction with consistent radiographic findings (eg, air space density) without an alternative explanation. Up to 10% of patients with CAP are hospitalized; of those, up to 1 in 5 require intensive care. Older adults (≥65 years) and those with underlying lung disease, smoking, or immune suppression are at highest risk for CAP and complications of CAP, including sepsis, acute respiratory distress syndrome, and death. Only 38% of patients hospitalized with CAP have a pathogen identified. Of those patients, up to 40% have viruses identified as the likely cause of CAP, with Streptococcus pneumoniae identified in approximately 15% of patients with an identified etiology of the pneumonia. All patients with CAP should be tested for COVID-19 and influenza when these viruses are common in the community because their diagnosis may affect treatment (eg, antiviral therapy) and infection prevention strategies. If test results for influenza and COVID-19 are negative or when the pathogens are not likely etiologies, patients can be treated empirically to cover the most likely bacterial pathogens. When selecting empirical antibacterial therapy, clinicians should consider disease severity and evaluate the likelihood of a bacterial infection-or resistant infection-and risk of harm from overuse of antibacterial drugs. Hospitalized patients without risk factors for resistant bacteria can be treated with β-lactam/macrolide combination therapy, such as ceftriaxone combined with azithromycin, for a minimum of 3 days. Systemic corticosteroid administration within 24 hours of development of severe CAP may reduce 28-day mortality. Conclusions: Community-acquired pneumonia is common and may result in sepsis, acute respiratory distress syndrome, or death. First-line therapy varies by disease severity and etiology. Hospitalized patients with suspected bacterial CAP and without risk factors for resistant bacteria can be treated with β-lactam/macrolide combination therapy, such as ceftriaxone combined with azithromycin, for a minimum of 3 days.

Infectious Pulmonary Diseases

Causative Agent Distribution and Antibiotic Therapy Assessment among Adult Patients with Community Acquired Pneumonia in Chinese Urban Population.

Epidemiology, Treatment, and Prevention of Nosocomial Bacterial Pneumonia

Microbial Etiology of Pneumonia: Epidemiology, Diagnosis and Resistance Pattern

Streptococcus pneumoniae epidemiology, pathogenesis and control

Advances in diagnosis and treatment of lung infection caused by gram-positive coccus

Multidrug Resistant Gram-Negative Bacteria in Community-Acquired Pneumonia

Antimicrobial Resistant Streptococcus pneumoniae: Prevalence, Mechanisms, and Clinical Implications

Community-Acquired Pneumonia: A Review

Aspiration pneumonia and pneumonitis: a spectrum of infectious/noninfectious diseases affecting the lung

Community-acquired pneumonia: The importance of the early detection of drug-resistant organisms

High proportion of drug-resistant isolates in adult community-acquired pneumonia from Northeast India: A hospital-based study

Current Status of Community-Acquired Pneumonia in Patients with Chronic Obstructive Pulmonary Disease

[Epidemiology and mechanisms of pneumonia in adults]

Advancements in the Management of Severe Community-Acquired Pneumonia: A Comprehensive Narrative Review

Epidemiology and Etiology of Community-Acquired Pneumonia

Complicated pneumonia in children

Management of pneumonia in critically ill patients

High Prevalence of Multidrug-Resistant Nonfermenters in Hospital-Acquired Pneumonia in Asia

Severe Community-Acquired Pneumonia in Immunocompromised Patients

Guideline for prevention of nosocomial pneumonia. Centers for Disease Control and Prevention